ADIL - adialpharma.com Company Long-Term Liabilities

This Adial Pharmaceuticals (ADIL) price chart shows the current level at 0.00. Adial Pharmaceuticals is focusing on bringing the AD04 drug to market for targeted impact on specific genotypes of individuals with alcoholism. A steady income is ensured by the long-term therapy cycle for dependent patients. High FDA certification costs and patent protection create insurmountable barriers to entry for new players.

This indicator aggregates the total sum of all credit obligations with a maturity exceeding one year, reacting inertly to changes in capital structure. The metric determines long-term solvency and default risk amid rising interest rates. For Adial Pharmaceuticals (ADIL), debt capital may be allocated to ensure secure logistics and certified transportation of drugs. Analyzing the magnitude of the issuer's long-term liabilities allows for the identification of critical peaks in credit load.